Stratos Wealth Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-2,089
Closed -$101K 2536
2018
Q3
$101K Buy
+2,089
New +$99K ﹤0.01% 1127
2018
Q2
Sell
-2,365
Closed -$99K 2619
2018
Q1
$99K Sell
2,365
-1,885
-44% -$82.1K ﹤0.01% 1215
2017
Q4
$185K Buy
+4,250
New +$181K 0.01% 912

Other funds holding XPH

Stratos Wealth Partners's XPH Position: Q4 2018 in Review

Stratos Wealth Partners sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2018, closing a stake of 2,089 shares — an estimated $101K sold.

Stratos Wealth Partners first reported a position in XPH in Q4 2017 and held it in 3 quarters. The position peaked at $185K in Q4 2017. 74 funds tracked by Wall St. Rank hold XPH as of Q4 2018.

  • Stratos Wealth Partners reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 2,089 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2018, an estimated $101K.
  • Stratos Wealth Partners first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's State Street SPDR S&P Pharmaceuticals ETF position peaked at $185K in Q4 2017.
  • 74 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.